"Clinically predictive preclinical efficacy testing services at your disposal"


Jussi Halleen - CEO, Pharmatest Services

Pharmatest has established a subsidiary in USA

Pharmatest Services LLC is a US based CRO operating in Massachusetts, where it offers preclinical efficacy services in oncology and skeletal diseases. The company is a fully owned subsidiary of Pharmatest Services Ltd based in Finland.

In skeletal diseases Pharmatest offers models of osteoporosis and osteoarthritis. In oncology Pharmatest has special expertise in clinically predictive orthotopic and metastasis models, and Pharmatest has been the global leading provider of models of bone metastasis since 2007. As bone experts Pharmatest also offers bone safety studies.

Jussi Halleen, CEO of Pharmatest comments: “Our US sales has grown more than 50% per year in the past years. We expect the growth to continue also in the coming years, and we established the LLC to be able to better serve our US customers. When the business grows it is our long-term goal to offer more jobs for skilled people in the US.”

Andrew Heiniluoma is the manager of the LLC and responsible for the operations. He says: “I am thrilled to see how the expertise and high quality preclinical services of Pharmatest will help American drug development companies to save time, money and effort, and at the same time develop compounds that are more effective in the clinic.”

Join us for an educational seminar about the importance of preclinical bone metastasis studies that Pharmatest will present in Boston on September 6 in an event held together with Taconic Biosciences. More detailed information about the event will be available later.